Skip to content
Screener

AnaptysBio, Inc. ANAB Royalty Management Company — Noncash Advance Future Royalties Interest Expense

Other segment segments

Biopharma Company
$0

Similar metrics at other companies

PTC Therapeutics logo
PTCTNoncash Royalty Revenue Sale Of Future Royalties
$46.84M+42.0%
PTC Therapeutics logo
PTCTNoncash Interest Expense Liability Related To Sale Of Future Royalties
$65.7M+32.3%
PVL
PVLANoncash Interest Expense Income Royalty Agreement
$2.04M+67.8%
Xencor logo
XNCRRoyalties — Expected royalty interest payments
$12M
Xencor logo
XNCRAdvance Future Royalty And Milestone Payments
$0
Xencor logo
XNCRAdvance Future Royalty And Milestone Payments
$0

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.62B+145%
Enterprise value$1.37B+117%
P/S+1.6×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept anab:NoncashAdvanceFutureRoyaltiesInterestExpense.

The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219515
Line itemBiopharmaRoyalty ManagementTotal
Total operating expenses52,8117,38260,193
(Loss) income from operations(52,811)18,174(34,637)
Interest income2,3283252,653
Non-cash interest expense(20,859)(20,859)
Other expense, net(1)(1)
Total other income (expense), net2,327(20,534)(18,207)
Loss before income taxes(50,484)(2,360)(52,844)
Provision for income taxes(40)(40)

Item 1. Consolidated Financial Statements

FAQ

What is AnaptysBio, Inc.'s royalty management company — noncash advance future royalties interest expense?
AnaptysBio, Inc. (ANAB) reported royalty management company — noncash advance future royalties interest expense of $20.86M in Q1 2026.
How has AnaptysBio, Inc.'s royalty management company — noncash advance future royalties interest expense changed year-over-year?
AnaptysBio, Inc.'s royalty management company — noncash advance future royalties interest expense increased by 15.5% year-over-year, from $18.06M to $20.86M.
What does royalty management company — noncash advance future royalties interest expense mean?
This metric represents the non-cash interest expense associated with financing arrangements or advances received against future royalty streams. It highlights the cost of capital tied to monetizing future cash flows upfront.

Ask your AI about AnaptysBio, Inc.'s royalty management company — noncash advance future royalties interest expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude